Withdrawn from the market (business decision)

Lesinurad

ZURAMPIC

Open Lesinurad in the interactive console ↗

Pronunciation: le-SIN-yoor-ad (zer-AM-pik)

Lesinurad ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Lesinurad ballicule

What it isURAT1 (and OAT4) inhibitor that increases renal uric acid excretion (uricosuric).

Why this oneAdd-on to a xanthine oxidase inhibitor for gout patients not reaching target serum urate on the XOI alone.

What limits itMust be taken with a xanthine oxidase inhibitor and adequate hydration because of renal risk, and it was withdrawn from the market in 2019.

Lesinurad molecular structure (skeletal formula) — Molecular structure: Lesinurad

Lesinurad prescription history

Animated chart of estimated U.S. prescriptions per year, Gout meds (1918–2026). Lesinurad enters in 2016.

⚠ BOXED WARNING

Acute renal failure

Principal riskBoxed warning: risk of acute renal failure, more common when used without a xanthine oxidase inhibitor.

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4

Overdose danger1 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk2 / 4

Open Lesinurad in the interactive console ↗

Self-check

What companion therapy is required with lesinurad?
A xanthine oxidase inhibitor.
Which transporters does lesinurad inhibit?
URAT1 and OAT4.